for the main comparison.

Oscillococcinum®compared with placebo for treatment of influenza
Patients/sample: participants aged over 12 years, with influenza‐like illness Settings: general or specialist practices, France and Germany Intervention: Oscillococcinum® twice a day for 5 days; Oscillococcinum® 3 times a day for 3 days Comparison: placebo
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk
	Placebo	Oscillococcinum®
Absence of symptoms at 48 hours ‐ patient assessment	90 per 1000	167 per 1000 (114 to 245)	RR 1.86 (1.27 to 2.73)	796 (2 studies)	⊕⊕⊝⊝ low
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence High quality: further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: we are very uncertain about the estimate.

The assumed risk is taken as that of the patients in the placebo groups of the two relevant trials. In the absence of information from other sources, calculations for low‐, medium‐ and high‐risk populations have not been calculated.